Silo Pharma price to sales ratio SILO
Market value divided by revenue over the last twelve months, since 2021.
- Today, Nov 2, 2026
- 35.5×
- 5-year median
- 76.3×
- Against its 5-year history
- 3rd
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 26.7× to 198×
- Peer median
- 0.4×
Silo Pharma's price to sales ratio is 35.5× as of Nov 2, 2026.
That is below its 5-year median of 76.3×, lower than on 97% of days in the last 5 years.
Over that time it ranged from 26.7× in May 2025 to 198× in Aug 2021.
The median for 7 healthcare stocks of a similar size is 0.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 35.5× | 34.7× | 101× |
| 2025 | 67.4× | 26.7× | 123× |
| 2024 | 58.5× | 37.4× | 95.6× |
| 2023 | n/m a value too high to mean anything | ||
| 2022 | 97.6× | 90.0× | 124× |
| 2021 | 91.7× | 86.5× | 198× |
Against its peers
Companies in Healthcare nearest Silo Pharma's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| SILOSilo Pharma | 35.5× |
| OXBROXBRIDGE RE HOLDINGS | 2.4× |
| EDUCEducational Development | 0.4× |
| GTIMGood Times Restaurants | 0.1× |
| MDRRMedalist Diversified | 1.9× |
| VIPVulcan Infrastructure & Power | 0.4× |
| BCGBinah Capital | 0.1× |
| MXCMexco Energy | 2.8× |
| Peer median | 0.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Silo Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.